Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies

被引：159

作者：

van Cruijsen, H ^{[1
]}

Giaccone, G ^{[1
]}

Hoekman, K ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands

来源：

INTERNATIONAL JOURNAL OF CANCER | 2005年 / 117卷 / 06期

关键词：

EGF; EGFR-inhibitors; VEGF; VEGF(R)-inhibitors; angiogenesis;

D O I：

10.1002/ijc.21479

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tumor-induced angiogenesis is essential for malignant growth. This mini review focuses on the role of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) and their receptors in this process, and the rationale to combine inhibitors of these growth factors as anticancer therapy. Concomitantly, targeting the VEGF(R) and the EGF(R) signaling pathway may circumvent the problem of acquired resistance to EGFR inhibitors. By targeting both pathways, the antiangiogenic effect may be more pronounced, which may lead to greater antitumor activity. Preliminary efficacy data from clinical trials encourage further exploration of this combined anticancer strategy. (c) 2005 Wiley-Liss, Inc.

引用

页码：883 / 888

页数：6

共 85 条

[51] A Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer [J].

Miller, KD ;

Trigo, JM ;

Wheeler, C ;

Barge, A ;

Rowbottom, J ;

Sledge, G ;

Baselga, J .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3369-3376

[52] Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer [J].

Miller, VA ;

Kris, WG ;

Shah, N ;

Patel, J ;

Azzoli, C ;

Gomez, J ;

Krug, LM ;

Pao, W ;

Rizvi, N ;

Pizzo, B ;

Tyson, L ;

Venkatraman, E ;

Ben-Porar, L ;

Memoli, N ;

Zakowski, M ;

Rusch, V ;

Heelan, RT .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1103-1109

[53] The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity [J].

Mukhopadhyay, D ;

Knebelmann, B ;

Cohen, HT ;

Ananth, S ;

Sukhatme, VP .

MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (09) :5629-5639

[54] A MODEL SYSTEM FOR TUMOR ANGIOGENESIS - INVOLVEMENT OF TRANSFORMING GROWTH FACTOR-ALPHA IN TUBE FORMATION OF HUMAN MICROVASCULAR ENDOTHELIAL-CELLS INDUCED BY ESOPHAGEAL CANCER-CELLS [J].

OKAMURA, K ;

MORIMOTO, A ;

HAMANAKA, R ;

ONO, M ;

KOHNO, K ;

UCHIDA, Y ;

KUWANO, M .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 186 (03) :1471-1479

[55] HB-EGF is a potent inducer of tumor growth and angiogenesis [J].

Ongusaha, PP ;

Kwak, JC ;

Zwible, AJ ;

Macip, S ;

Higashiyama, S ;

Taniguchi, N ;

Fang, L ;

Lee, SW .

CANCER RESEARCH, 2004, 64 (15) :5283-5290

[56] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[57] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [J].

Pao, W ;

Miller, VA ;

Politi, KA ;

Riely, GJ ;

Somwar, R ;

Zakowski, MF ;

Kris, MG ;

Varmus, H .

PLOS MEDICINE, 2005, 2 (03) :225-235

[58] EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J].

Pao, W ;

Miller, V ;

Zakowski, M ;

Doherty, J ;

Politi, K ;

Sarkaria, I ;

Singh, B ;

Heelan, R ;

Rusch, V ;

Fulton, L ;

Mardis, E ;

Kupfer, D ;

Wilson, R ;

Kris, M ;

Varmus, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13306-13311

[59] Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma [J].

Parikh, AA ;

Liu, WB ;

Fan, F ;

Stoeltzing, O ;

Reinmuth, N ;

Bruns, CJ ;

Bucana, CD ;

Evans, DB ;

Ellis, LM .

CANCER, 2003, 98 (04) :720-729

[60] AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma Xenografts in nude mice [J].

Park, YW ;

Younes, MN ;

Jasser, SA ;

Yigitbasi, OG ;

Zhou, G ;

Bucana, CD ;

Bekele, BN ;

Myers, JN .

CLINICAL CANCER RESEARCH, 2005, 11 (05) :1963-1973

← 1 2 3 4 5 6 7 8 9 →